Compare Deutsche Bank AG (DB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs State Street SPDR S&P Biotech ETF — how do they compare? Deutsche Bank AG trades at $33.65 (market cap $63.13B), while State Street SPDR S&P Biotech ETF trades at $149.65 (market cap $10.08B). The key difference: Deutsche Bank AG is far larger — about 6.3× State Street SPDR S&P Biotech ETF's market cap, and Deutsche Bank AG pays a 3.47% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| DB | XBI | |
|---|---|---|
Market Cap | $63.13B | $10.08B |
Volume | 3,260,488 | 9,534,635 |
Sector | Financials | Broad Market / Factor |
52-Week High | $41.56 | $169.55 |
52-Week Low | $28.37 | $104.99 |
Typical Hold Time | 80 Days | 37 Days |
Enterprise Value | $75.71B | — |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.63, down 4.27% amid a bearish technical signal. The stock shows attractive valuation with a P/E of 9.1 and P/B of 0.71, while recent earnings beat expectations in two of the last three quarters. Net income surged to $6.93B in 2025, though Q3 2026 investment bank revenue is expected flat to slightly down. Cash flow improved significantly with net cash flow of $7.61B in 2025.
The outlook is mixed: strong fundamentals and low valuation support upside, but bearish technicals and cautious analyst consensus (57.58% hold) indicate near-term headwinds. Key risks include revenue volatility in investment banking and macroeconomic sensitivity. The stock offers value potential if execution on 2028 targets holds.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
